Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMA-CNS: HCT-ASCT vs R-MP in Elderly PCNSL
NCT06830421Phase 3Recruiting
- Sponsor
- University Hospital Freiburg
- Start
- Aug 2023
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine, busulfan and thiotepa in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by University Hospital Freiburg. Primary endpoint: Progression Free Survival at 6 years. Started Aug 2023; status: recruiting.
02
Drugs
cytarabinebusulfanthiotepa
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06830421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830421.